Skip to Main Content

While Covid-19 struck a blow to a vast number of clinical trials around the world, the pandemic may turn out to be a boon for bringing gene therapies to more people in the coming years.

“Who would have predicted three years ago that we’d now be having billions of doses manufactured of mRNA packaged in a lipid nanoparticle?” Sekar Kathiresan, CEO of Verve Therapeutics said Tuesday during the STAT Breakthrough Science Summit

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment